Stocks · News reference
SciSparc Says NeuroThera Labs Advances Participant Enrollment For Clinical Trial Assessing SCI-210 Treatment For Symptoms Associated With Autism Spectrum Disorder
SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
SciSparc Agrees to Convert $2.02M Convertible Note Into Ordinary Shares At $1.50/Share
SciSparc Shares Halted On Circuit Breaker To The Downside, Stock Now Down -45.45%
SciSparc Shares Halted On Circuit Breaker To The Downside, Stock Now Down -23.69%
Clearmind Medicine Announces Three U.S. Patent Applications Covering Novel Proprietary Combinations Of LSD, Ketamine And Ibogaine With N-Acylethanolamines Such As Palmitoylethanolamide
The covered applications address potential therapeutic uses across a range of indications, including mental health disorders, such as depression, post-traumatic stress disorder ("PTSD"), pain and substance use
SciSparc Unit Neurothera Labs And Clearmind Medicine Publish U.S. Patent Application For A Novel Combination Of 3,4-Methylenedioxymethamphetamine And N-Acylethanolamines For Use In Methods Of Treating Post-Traumatic Stress Disorder, Anxiety And Eating Disorders